Also known as CTIU2317-A082304-S2402 (I’ll stick with “PROSPECT-Lung”), the trial is co-led by the Alliance and SWOG, with the Alliance heading up administration. Co-chaired by Drs. Daniel Morgensztern (Alliance) and Raid Aljumaily (SWOG), it compares perioperative systemic therapy to adjuvant systemic therapy in patients with resectable early-stage non-small cell lung cancer (NSCLC).
Blinatumomab plus chemotherapy significantly improved 3-year DFS rates vs chemotherapy alone in pediatric patients with standard-risk pediatric B-ALL.
Eunice S. Wang, MD, on ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.
Sacituzumab tirumotecan has received breakthrough therapy designation from the FDA for use in select patients with EGFR+ non–small cell lung cancer.
Es una de las más extensas de España con entrada submarina
The Northwestern University Nervous System Tumor Bank provides scientists with high-quality, patient-derived biospecimens to support preclinical and translational neuro-oncology research.
Disitamab vedotin showed early activity in HER2-expressing metastatic breast cancer with abnormal PAM pathway activation.
Research by Fred Hutch Cancer Center genetic epidemiologist Burcu Darst, PhD, and scientists from the Canary Prostate Active Surveillance Study (PASS), suggests that a patient’s…
This model-based study using population-level cancer mortality data evaluates the association of prevention, screening, and treatment interventions with cumulative number of cancer deaths averted from…
Meaningful thresholds for interpreting changes in 3 EORTC QLQ-CLL17 domain scores have been identified in a PRO analysis of the TRANSCEND CLL 004 trial.
